2025
Costs and cost-effectiveness of integrated screening for non-communicable diseases in TB contacts
Hamada Y, Mukora R, Pelusa R, Ntshiqa T, Shedrawy J, Velen K, Abubakar I, Charalambous S, Walker S, Rangaka M. Costs and cost-effectiveness of integrated screening for non-communicable diseases in TB contacts. IJTLD OPEN 2025, 2: 160-165. PMID: 40092516, PMCID: PMC11906026, DOI: 10.5588/ijtldopen.24.0625.Peer-Reviewed Original ResearchNon-communicable diseasesDisability-adjusted life yearsNon-communicable disease screeningNon-communicable disease casesIncremental cost-effectiveness ratioIncremental costCardiovascular diseaseCross-sectional studyHigh riskCost-effectiveHousehold contact investigationCVD riskCare costsCost-effectiveness ratioHealthcare perspectiveAssessed patientsLife yearsProvider costsIntegrated screeningImprove cost-effectivenessPrioritising individualsContact investigationTB contactDrug costsRisk
2024
Associations Among Sleep, Pain, and Medications for Opioid Use Disorder: a Scoping Review
Hsaio C, DiMeola K, Jegede O, Funaro M, Langstengel J, Yaggi H, Barry D. Associations Among Sleep, Pain, and Medications for Opioid Use Disorder: a Scoping Review. Current Addiction Reports 2024, 11: 965-981. PMID: 39886383, PMCID: PMC11781152, DOI: 10.1007/s40429-024-00606-7.Peer-Reviewed Original ResearchOpioid use disorderOUD severityUse disorderTreatment characteristicsOpioid use disorder treatment settingsTreatment of sleepDosing scheduleDisorder severityOpioidPainWeb of ScienceAssessed patientsCochrane LibraryMeasures of sleepMOUD treatmentCurrent evidenceMOUDSleepSleep disturbanceProvider preferencesPatientsStudy examined sleepDisordersTreatment settingsMedicationValidation of Metallothionein Immunohistochemistry as a Highly Sensitive Screening Test for Wilson Disease
Stokes N, Patil A, Adeyi O, Bhalla A, Brown I, Byrnes K, Calderaro J, Chen D, Chen W, Cooper C, Dhall D, Frankel W, Gooch G, Gonzalez R, Hammer S, Hale G, Lagana S, McKenzie C, Allende D, Moreira R, Nakhleh R, Nalbantoglu I, Pai R, Salomao M, Schaeffer D, Shih A, Shin J, Simoes C, Vij M, Rela M, Xue Y, Yantiss R, Sabatto B, Graham R. Validation of Metallothionein Immunohistochemistry as a Highly Sensitive Screening Test for Wilson Disease. Modern Pathology 2024, 38: 100628. PMID: 39384020, DOI: 10.1016/j.modpat.2024.100628.Peer-Reviewed Original ResearchWilson's diseaseHistological featuresRare autosomal recessive conditionChronic cholestatic diseaseProtean clinical manifestationsEvaluation of patientsAutosomal recessive conditionSensitive screening testCase of WDCost-effective screening toolRoutine histologic sectionsMedian ageNeedle biopsyCholestatic diseasesWD patientsFibrosis stageClinical manifestationsHistopathological patternsATP7B mutationsHistological patternWD diagnosisTissue specimensAssessed patientsImmunohistochemistryMasson's trichrome
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply